InMed Pharmaceuticals is the first company to advance cannabinol (CBN) into clinical trials for therapeutic development. It has begun a Phase 1 clinical trial in healthy volunteers for INM-755 CBN cream, its lead program in epidermolysis bullosa (EB). CBN is also the active pharmaceutical ingredient in InMed’s second program in glaucoma. In this video, InMed CEO Eric A. Adams talks about CBN’s distinct structural properties and its potential in treatments for skin and ocular diseases.
InMed’s CEO Eric A. Adams presents at Edison Open House: Global Healthcare 2021
InMed Pharmaceuticals CEO, Eric A. Adams, is interviewed by Science Journalist and Broadcaster Vivienne Parry Obe at the Edison Open House: Global Healthcare Conference 2021.